Logo image of STIM

NEURONETICS INC (STIM) Stock Fundamental Analysis

USA - NASDAQ:STIM - US64131A1051 - Common Stock

2.89 USD
-0.15 (-4.93%)
Last: 10/16/2025, 3:59:06 PM
Fundamental Rating

2

Taking everything into account, STIM scores 2 out of 10 in our fundamental rating. STIM was compared to 191 industry peers in the Health Care Equipment & Supplies industry. STIM may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, STIM is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year STIM has reported negative net income.
STIM had a negative operating cash flow in the past year.
STIM had negative earnings in each of the past 5 years.
In the past 5 years STIM always reported negative operating cash flow.
STIM Yearly Net Income VS EBIT VS OCF VS FCFSTIM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

STIM has a Return On Assets of -36.24%. This is in the lower half of the industry: STIM underperforms 60.21% of its industry peers.
STIM has a Return On Equity of -179.75%. This is in the lower half of the industry: STIM underperforms 69.11% of its industry peers.
Industry RankSector Rank
ROA -36.24%
ROE -179.75%
ROIC N/A
ROA(3y)-29.62%
ROA(5y)-29.17%
ROE(3y)-103.71%
ROE(5y)-91.08%
ROIC(3y)N/A
ROIC(5y)N/A
STIM Yearly ROA, ROE, ROICSTIM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200

1.3 Margins

Looking at the Gross Margin, with a value of 56.15%, STIM is in line with its industry, outperforming 52.88% of the companies in the same industry.
In the last couple of years the Gross Margin of STIM has remained more or less at the same level.
STIM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 56.15%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.88%
GM growth 5Y-0.84%
STIM Yearly Profit, Operating, Gross MarginsSTIM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

More info and screens

2

2. Health

2.1 Basic Checks

STIM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, STIM has more shares outstanding
Compared to 5 years ago, STIM has more shares outstanding
Compared to 1 year ago, STIM has an improved debt to assets ratio.
STIM Yearly Shares OutstandingSTIM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
STIM Yearly Total Debt VS Total AssetsSTIM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

Based on the Altman-Z score of -3.24, we must say that STIM is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -3.24, STIM is not doing good in the industry: 65.97% of the companies in the same industry are doing better.
STIM has a Debt/Equity ratio of 2.05. This is a high value indicating a heavy dependency on external financing.
STIM's Debt to Equity ratio of 2.05 is on the low side compared to the rest of the industry. STIM is outperformed by 83.77% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.05
Debt/FCF N/A
Altman-Z -3.24
ROIC/WACCN/A
WACC8.74%
STIM Yearly LT Debt VS Equity VS FCFSTIM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

A Current Ratio of 2.02 indicates that STIM has no problem at all paying its short term obligations.
STIM's Current ratio of 2.02 is on the low side compared to the rest of the industry. STIM is outperformed by 63.87% of its industry peers.
STIM has a Quick Ratio of 1.84. This is a normal value and indicates that STIM is financially healthy and should not expect problems in meeting its short term obligations.
STIM has a Quick ratio (1.84) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 2.02
Quick Ratio 1.84
STIM Yearly Current Assets VS Current LiabilitesSTIM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for STIM have decreased by -0.89% in the last year.
STIM shows a strong growth in Revenue. In the last year, the Revenue has grown by 54.18%.
STIM shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.63% yearly.
EPS 1Y (TTM)-0.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.55%
Revenue 1Y (TTM)54.18%
Revenue growth 3Y10.63%
Revenue growth 5Y3.63%
Sales Q2Q%131.66%

3.2 Future

The Earnings Per Share is expected to grow by 18.70% on average over the next years. This is quite good.
STIM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 25.79% yearly.
EPS Next Y57.31%
EPS Next 2Y29.23%
EPS Next 3Y21.45%
EPS Next 5Y18.7%
Revenue Next Year109.15%
Revenue Next 2Y52.89%
Revenue Next 3Y38.05%
Revenue Next 5Y25.79%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
STIM Yearly Revenue VS EstimatesSTIM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 50M 100M 150M 200M
STIM Yearly EPS VS EstimatesSTIM Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -0.5 -1 -1.5 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

STIM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year STIM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
STIM Price Earnings VS Forward Price EarningsSTIM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
STIM Per share dataSTIM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as STIM's earnings are expected to grow with 21.45% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.23%
EPS Next 3Y21.45%

More info and screens

0

5. Dividend

5.1 Amount

STIM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEURONETICS INC

NASDAQ:STIM (10/16/2025, 3:59:06 PM)

2.89

-0.15 (-4.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-05 2025-08-05/bmo
Earnings (Next)11-10 2025-11-10/bmo
Inst Owners27.71%
Inst Owner Change-0.14%
Ins Owners6.38%
Ins Owner Change5.42%
Market Cap191.09M
Analysts82.22
Price Target6.63 (129.41%)
Short Float %15.64%
Short Ratio4.48
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-78.26%
Min EPS beat(2)-91.81%
Max EPS beat(2)-64.71%
EPS beat(4)0
Avg EPS beat(4)-74.53%
Min EPS beat(4)-91.81%
Max EPS beat(4)-54.06%
EPS beat(8)2
Avg EPS beat(8)-34.91%
EPS beat(12)6
Avg EPS beat(12)-13.79%
EPS beat(16)8
Avg EPS beat(16)-9.34%
Revenue beat(2)2
Avg Revenue beat(2)4.68%
Min Revenue beat(2)1.52%
Max Revenue beat(2)7.85%
Revenue beat(4)3
Avg Revenue beat(4)4.16%
Min Revenue beat(4)-5.05%
Max Revenue beat(4)12.31%
Revenue beat(8)4
Avg Revenue beat(8)0.37%
Revenue beat(12)7
Avg Revenue beat(12)1.37%
Revenue beat(16)10
Avg Revenue beat(16)1.33%
PT rev (1m)0%
PT rev (3m)-4.88%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-90%
EPS NY rev (1m)0%
EPS NY rev (3m)-60.75%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.18%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.23%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.72
P/FCF N/A
P/OCF N/A
P/B 7.04
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.13
EYN/A
EPS(NY)-0.45
Fwd EYN/A
FCF(TTM)-0.54
FCFYN/A
OCF(TTM)-0.52
OCFYN/A
SpS1.68
BVpS0.41
TBVpS-0.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -36.24%
ROE -179.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 56.15%
FCFM N/A
ROA(3y)-29.62%
ROA(5y)-29.17%
ROE(3y)-103.71%
ROE(5y)-91.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.88%
GM growth 5Y-0.84%
F-Score3
Asset Turnover0.83
Health
Industry RankSector Rank
Debt/Equity 2.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 34.15%
Cap/Sales 0.85%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.02
Quick Ratio 1.84
Altman-Z -3.24
F-Score3
WACC8.74%
ROIC/WACCN/A
Cap/Depr(3y)129%
Cap/Depr(5y)137.27%
Cap/Sales(3y)3.43%
Cap/Sales(5y)3.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.55%
EPS Next Y57.31%
EPS Next 2Y29.23%
EPS Next 3Y21.45%
EPS Next 5Y18.7%
Revenue 1Y (TTM)54.18%
Revenue growth 3Y10.63%
Revenue growth 5Y3.63%
Sales Q2Q%131.66%
Revenue Next Year109.15%
Revenue Next 2Y52.89%
Revenue Next 3Y38.05%
Revenue Next 5Y25.79%
EBIT growth 1Y-28.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year30.12%
EBIT Next 3Y22.25%
EBIT Next 5Y16.54%
FCF growth 1Y1.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-2.53%
OCF growth 3YN/A
OCF growth 5YN/A